BridgeBio presents post-hoc analysis evaluating acoramidis

BridgeBio Pharma presented a post-hoc analysis evaluating the effect of acoramidis on the composite endpoint of ACM and recurrent CVH events in its Phase 3 ATTRibute-CM study in ATTR-CM at the Heart Failure Society of America Annual Scientific Meeting 2024. ATTRibute-CM was designed to evaluate the efficacy and safety of acoramidis, an investigational, near-complete, orally-administered, small molecule stabilizer of TTR. “We are proud to share the results of this post-hoc analysis demonstrating a highly significant reduction in all-cause mortality and the sum of recurrent CV-related hospitalizations in patients with ATTR-CM at 30 Months in the ATTRibute-CM trial,” said Jonathan Fox, M.D., Ph.D., chief medical officer of BridgeBio Cardiorenal. “At BridgeBio, we believe in the importance of both data transparency and continued communication of additional details of this landmark trial, especially to assist physicians choosing ATTR-CM therapies for their patients who rely on their healthcare provider’s recommendations. By conducting and presenting multiple analyses, we hope to both advance the clinical science around ATTR-CM trials and highlight the potential for acoramidis to be a meaningful treatment option for patients.” The analysis, shared by Daniel Judge, M.D., professor of medicine and cardiology at the Medical University of South Carolina in an oral presentation, included: A 42% reduction in composite ACM and recurrent CVH events at 30 months observed with acoramidis treatment compared to placebo by applying a negative binomial regression model; A 42% reduction in the total number of ACM and recurrent CVH events per patient observed over 30 months with acoramidis treatment compared to placebo; A 30.5% hazard reduction in ACM and recurrent CVH events at 30 months observed with acoramidis treatment compared to placebo by applying the Andersen-Gill model. “This post-hoc analysis provides further evidence that near-complete TTR stabilization with acoramidis can improve clinical outcomes for patients with ATTR-CM. The reduction of hospitalizations and all-cause mortality seen in ATTRibute-CM heightens the case for acoramidis as a first-line therapy given its potential to improve the overall quality of life for patients,” said Dr. Judge.